SG121852A1 - Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 - Google Patents
Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1Info
- Publication number
- SG121852A1 SG121852A1 SG200307655A SG200307655A SG121852A1 SG 121852 A1 SG121852 A1 SG 121852A1 SG 200307655 A SG200307655 A SG 200307655A SG 200307655 A SG200307655 A SG 200307655A SG 121852 A1 SG121852 A1 SG 121852A1
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- transporter protein
- atp binding
- binding cassette
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14026499P | 1999-06-18 | 1999-06-18 | |
US15387299P | 1999-09-14 | 1999-09-14 | |
US16657399P | 1999-11-19 | 1999-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG121852A1 true SG121852A1 (en) | 2006-05-26 |
Family
ID=27385472
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200307655A SG121852A1 (en) | 1999-06-18 | 2000-06-16 | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
SG200307656A SG121853A1 (en) | 1999-06-18 | 2000-06-16 | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200307656A SG121853A1 (en) | 1999-06-18 | 2000-06-16 | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
Country Status (19)
Country | Link |
---|---|
EP (2) | EP1218515B1 (de) |
JP (4) | JP2003506097A (de) |
KR (2) | KR20020012612A (de) |
CN (2) | CN100513570C (de) |
AR (2) | AR024576A1 (de) |
AT (1) | ATE422545T1 (de) |
AU (3) | AU5743400A (de) |
BR (2) | BR0011696A (de) |
CA (2) | CA2375781A1 (de) |
DE (1) | DE60041545D1 (de) |
HK (2) | HK1046427A1 (de) |
IL (2) | IL147022A0 (de) |
MX (2) | MXPA01013175A (de) |
NO (2) | NO20016114L (de) |
NZ (3) | NZ529785A (de) |
SG (2) | SG121852A1 (de) |
TR (2) | TR200200440T2 (de) |
TW (2) | TWI304737B (de) |
WO (2) | WO2000078971A2 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055318A2 (en) | 1999-03-15 | 2000-09-21 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
EP1854880A1 (de) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Verfahren und Reagenzien zur Modulation von Cholesterinspiegeln |
WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
AU1291901A (en) * | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
BR0110541A (pt) | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
EP1203588A1 (de) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-unabhängige Regulierung des ABC1 Promotors mit OncostatinM |
US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
AU2002317093A1 (en) * | 2001-07-03 | 2003-01-21 | University Of British Columbia | Screening processes for agents modulating cholesterol levels |
CN1568199A (zh) * | 2001-10-12 | 2005-01-19 | 格勒兰制药株式会社 | 低hdl血症改善剂 |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
ATE521599T1 (de) | 2001-12-21 | 2011-09-15 | X Ceptor Therapeutics Inc | Heterocyclische modulatoren von nukleären rezeptoren |
AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
DE60335911D1 (de) | 2002-12-20 | 2011-03-10 | Daiichi Sankyo Co Ltd | Isochinolinonderivate und deren verwendung als medikamente |
RU2006105646A (ru) | 2003-07-23 | 2007-09-10 | Экселиксис, Инк. (Us) | Производные азепина в качестве фармацевтических агентов |
WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
EP1888640B1 (de) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Verbesserte nanokörper gegen tumornekrosefaktor-alpha |
MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
WO2007002559A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
EP2070919B1 (de) | 2006-11-24 | 2012-10-10 | Hykes Laboratories LLC | Spirochinonverbindung und pharmazeutische zusammensetzung |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
EP2247616A2 (de) | 2008-03-05 | 2010-11-10 | Ablynx N.V. | Neuartige antigenbindende dimerkomplexe, verfahren zu ihrer herstellung und verwendungen davon |
CA2720763A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
EP2403873A1 (de) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon |
WO2010120508A2 (en) * | 2009-03-31 | 2010-10-21 | The General Hospital Corporation | Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders |
CN105399828B (zh) | 2009-04-10 | 2021-01-15 | 埃博灵克斯股份有限公司 | 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽 |
EP2435410B1 (de) | 2009-05-28 | 2017-01-18 | Exelixis Patent Company LLC | Lxr-modulatoren |
WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
JP5933573B2 (ja) | 2010-11-08 | 2016-06-15 | ノバルティス アーゲー | Cxcr2結合ポリペプチド |
TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン.ヴェー. | IgEに対する免疫グロブリン単一可変ドメイン |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
MX2014015205A (es) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear. |
US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
EP2967073B9 (de) | 2013-03-15 | 2019-04-10 | Bristol-Myers Squibb Company | Lxr-modulatoren |
WO2014144037A1 (en) | 2013-03-15 | 2014-09-18 | Bristol-Myers Squibb Company | Lxr modulators |
NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
SG11201803976VA (en) | 2015-11-27 | 2018-06-28 | Ablynx Nv | Polypeptides inhibiting cd40l |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
WO2018091606A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
KR20200013247A (ko) | 2017-06-02 | 2020-02-06 | 아블린쓰 엔.브이. | 아그레칸 결합 면역글로불린 |
BR112019024333A2 (pt) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | imunoglobulinas de ligação adamts |
WO2018220235A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Mmp13 binding immunoglobulins |
US11813307B2 (en) | 2017-06-02 | 2023-11-14 | Merck Patent Gmbh | Polypeptides binding ADAMTS5, MMP13 and aggrecan |
CN115433733A (zh) | 2021-06-04 | 2022-12-06 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0110541A (pt) * | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
-
2000
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Application Discontinuation
- 2000-06-16 EP EP00942914A patent/EP1218515B1/de not_active Expired - Lifetime
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active IP Right Cessation
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 EP EP00942867A patent/EP1190065A2/de not_active Withdrawn
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Application Discontinuation
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Application Discontinuation
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
-
2001
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
-
2002
- 2002-09-26 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2002-11-13 HK HK02108234.7A patent/HK1046708A1/zh unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG121852A1 (en) | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 | |
EP1212065A4 (de) | Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels | |
AU7912100A (en) | Pharmaceutical composition comprising an antigen | |
EP1165586A4 (de) | Tcl-1b gene und proteine und verwandte methoden und verfahren | |
EE200100649A (et) | A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks | |
IL212926A0 (en) | METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES | |
AU2002219258A1 (en) | Method and system for administering digital collectible cards | |
IL201751A (en) | Compounds that bind il-17-like cytokine and antibodies | |
AU3808700A (en) | Compositions and methods for recombinant adeno-associated virus production | |
AU3864900A (en) | Compositions and methods for their preparation from (lepidium) | |
IL206565A0 (en) | An antibody immunospecific for an igs4 polypeptide | |
AU2977500A (en) | Advanced antigen presentation platform | |
AU2002365111A1 (en) | Methods for identifying and using marr family polypeptide binding compounds | |
EP1059579A3 (de) | Datenprozessor und Verfahren zur Registerspeicherumschaltung | |
EP0987942A4 (de) | Pharmazeutische zusammensetzung und verfahren zu ihrer verwendung | |
AU6841300A (en) | Human antibodies or fragments thereof binding to hla-cw6 | |
AU8513698A (en) | Methods and compositions for designing vaccines | |
EP1035204A4 (de) | An steroidhormon bindendes protein | |
AU2002316178A1 (en) | Compositions and methods for binding agglomeration proteins | |
AU5931600A (en) | Lcat recombinant cell line compositions and methods | |
AU2875600A (en) | Methods and compositions for enhancing fibroblast migration | |
AU5494700A (en) | Rna metabolism proteins | |
GB9929923D0 (en) | Antigen preparations | |
AU4833500A (en) | Antibody vaccine for autoimmune diseases | |
AU2003242848A1 (en) | Nuclear hormone receptor ligano-binding domain containing protein |